Document Detail

Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
MedLine Citation:
PMID:  17292404     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Induction with the use of monoclonal antibodies targeting the alpha-chain (CD25) of the high-affinity IL2 receptor may avoid many of the adverse events associated with polyclonal antibodies and significantly impact on rejection-free long-term survival in orthotopic liver transplantation (OLT).
METHODS: Forty-two consecutive deceased donor primary OLT were retrospectively analyzed. All patients received two 20-mg doses of basiliximab (days 0 and 4 after OLT) followed by tacrolimus (0.15 mg/kg/day; 10-15 ng/mL target trough levels), and steroids (methylprednisolone 1 g intraoperatively followed by tapering doses). Mycophenolate mofetil (MMF) 1 g every 12 h was added to the drug combination as needed. The mean follow-up period was 19.3 months (range: 4.8-35.9 months).
RESULTS: The average Model for End-Stage Liver Disease score was 26 (range: 15-40). A total of 39 patients (93%) remained rejection-free during follow-up with an actuarial rejection-free probability of 95% within 3 months. The actuarial patient and graft survival rate (Kaplan-Meier estimated) at 2 years was 93%. Twenty-five patients (60%) were completely off steroids within 3 months post-OLT (mean: 51.1 days, range: 10-90 days). By the 10th month post-OLT, 30/39 (77%) of the patients were completely off steroids. At last follow-up, 30/39 (77%) are on tacrolimus monotherapy with an average dose of 4 mg per day. Six patients (15%) are on double therapy, receiving a combination of tacrolimus and prednisone (two patients) or tacrolimus and MMF (two patients) or tacrolimus and mycophenolic acid (two patients). Only three patients (8%) are receiving triple therapy at last follow-up. Nine patients (21%) experienced at least one episode of infection. Only six (26%) of a total of 23 hepatitis C virus (HCV) recipients developed histology-proven HCV recurrence, with a mean onset of recurrence post-OLT of 3.2 months (range: 1.3-6.3 months). Of these six patients, two are presently undergoing treatment with interferon and ribavirin, one was treated and became HCV RNA negative, one was not treated, one declined treatment, and two died of HCV recurrence. None of the 42 study patients developed cytomegalovirus infection or posttransplant lymphoproliferative disease.
CONCLUSIONS: These preliminary data suggest that basiliximab, given in combination with a tacrolimus-based immunosuppressive regimen, is safe and associated with a low incidence of acute rejection and excellent short-term rejection-free graft and patient survival rate after OLT.
Carlo B Ramirez; Cataldo Doria; Fabrizio di Francesco; Maurizio Iaria; Yoogoo Kang; Ignazio R Marino
Related Documents :
22528134 - Current view: indications for extracorporeal lipid apheresis treatment.
24581874 - The functional impact of bilateral reverse total shoulder arthroplasty.
8023874 - Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in behç...
20505654 - Addition of cyclophosphamide to steroids provides no benefit compared with steroids alo...
23719354 - Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine f...
2023444 - Valve-related complications with the hancock i porcine bioprosthesis. a twelve- to four...
Publication Detail:
Type:  Journal Article     Date:  2007-02-08
Journal Detail:
Title:  The Journal of surgical research     Volume:  138     ISSN:  0022-4804     ISO Abbreviation:  J. Surg. Res.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-12     Completed Date:  2007-05-15     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0376340     Medline TA:  J Surg Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  198-204     Citation Subset:  IM    
Division of Transplantation, Department of Surgery, Jefferson Medical College and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Graft Rejection / drug therapy*,  mortality,  pathology
Immunosuppressive Agents / administration & dosage*,  adverse effects
Interleukin-2 Receptor alpha Subunit / immunology*
Liver Transplantation*
Methylprednisolone / administration & dosage,  adverse effects
Middle Aged
Mycophenolic Acid / administration & dosage,  adverse effects,  analogs & derivatives
Postoperative Complications
Recombinant Fusion Proteins / administration & dosage*,  adverse effects
Retrospective Studies
Survival Rate
Tacrolimus / administration & dosage,  adverse effects
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Interleukin-2 Receptor alpha Subunit; 0/Recombinant Fusion Proteins; 0/basiliximab; 109581-93-3/Tacrolimus; 24280-93-1/Mycophenolic Acid; 83-43-2/Methylprednisolone; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does impaired TH1/TH2 balance cause postoperative infectious complications in colorectal cancer surg...
Next Document:  Retrospective analysis of local sensorimotor deficits after radial artery harvesting for coronary ar...